This is a routine technical amendment to the merger structure. The key change is the halving of post-merger shares outstanding from 10M to 5M, which mechanically doubles the per-share value of the Combined Company's equity for a given enterprise value. The CVR Agreement amendments improve transparency for CVR holders with quarterly reporting. Monitor for shareholder vote on the merger and subsequent closing.
Price Chart
Executive Summary
Chemomab Therapeutics Ltd. filed a 6-K reporting Amendment No. 2 to its Domestication Merger Agreement, which reduces the number of Chemomab Parent shares to be issued in the Domestication Merger from 10,000,000 to 5,000,000, and updates the form of Contingent Value Rights Agreement (CVR Agreement) to add quarterly status reporting obligations for CVR holders and remove registration-statement tolling provisions. The amendment is described as technical, not changing the economic value or relative ownership allocation between Chemomab and Scipher.
Key Facts
- Amendment No. 2 reduces the number of Chemomab Parent shares outstanding post-Merger from 10,000,000 to 5,000,000.
- The amendment is described as technical and does not change the consideration payable, economic value, or relative ownership allocation between Chemomab and Scipher.
- The CVR Agreement was amended to require Chemomab Parent to provide quarterly Status Reports to CVR holders within 45 days after each calendar quarter.
- The CVR Agreement amendment removed the tolling of payment periods pending registration statement effectiveness and the related requirement to pay milestones entirely in cash if the registration statement does not become effective within 90 days.
- Milestone 1 Payment is $40,000,000 (Phase III initiation or disposition of Product in PSC).
- Milestone 2 Payment is $10,000,000 (FDA approval in any indication).
- CVR Expense Cap is $600,000.
- CVR Term ends on the seventh anniversary of the CVR Agreement date.
- The Product is Nebokitug (CM-101) for Primary Sclerosing Cholangitis (PSC).
Financial Impact
No financial impact from this filing. The amendment is technical and does not change the economic value of the transaction. The CVR Agreement provides for up to $50,000,000 in milestone payments ($40M for Milestone 1, $10M for Milestone 2), but these are contingent on future events and unchanged by this filing.
Risk Factors
- Risk that the Domestication Merger or Merger with Scipher does not close.
- CVR milestone payments are highly speculative and may never be paid; the filing states it is 'highly possible that there will not be any Milestone Payments'.
- Parent retains sole discretion over the Product Program and may terminate it, subject only to a limited Development Covenant to initiate a Phase II trial within 12 months of FDA IND acceptance.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004796 |
| Exhibit: exhibit_2-1.htm | 0001178913-26-004796 |
| Document: zk2636237.htm | 0001178913-26-004796 |
| Document: 0001178913-26-004796-index-headers.html | 0001178913-26-004796 |
| Document: 0001178913-26-004796-index.html | 0001178913-26-004796 |
| Document: 0001178913-26-004796.txt | 0001178913-26-004796 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $1.18 $1.15 | ▼ −2.54% | ▼ −3.07% | $1.00 (−15.25%) |
Sep 30, 2026 26d ago | 6-K | $1.30 $1.43 | ▲ +10.00% | ▲ +9.26% | $1.00 (−23.08%) |
Aug 19, 2026 9w ago | 6-K | $2.09 $2.07 | ▼ −0.96% | ▼ −0.12% | $1.00 (−52.15%) |
Aug 19, 2026 9w ago | Press Release | $2.09 $2.07 | ▲ +0.96% | ▲ +0.12% | $1.00 (+52.15%) |
Jul 8, 2026 15w ago | 6-K | $1.97 $1.83 | ▼ −7.11% | ▼ −7.95% | $1.00 (−49.24%) |
Jun 2, 2026 20w ago | 6-K | $1.72 $1.80 | ▲ +4.65% | ▲ +4.25% | $1.00 (−41.86%) |
May 14, 2026 23w ago | 6-K | $1.70 $1.66 | ▼ −2.35% | ▼ −1.13% | $1.00 (−41.18%) |
May 14, 2026 23w ago | Press Release | $1.70 $1.66 | ▼ −2.35% | ▼ −1.13% | $1.00 (−41.18%) |
May 6, 2026 24w ago | 6-K | $1.74 $1.77 | ▲ +1.72% | ▲ +0.89% | $1.00 (−42.53%) |
Mar 19, 2026 31w ago | Press Release | $1.93 $1.78 | ▼ −7.77% | ▼ −6.03% | $1.00 (−48.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers